Screener
Biohaven BHVN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Biohaven in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Biohaven’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001935979-26-000045
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from issuance of common shares | 178,884 | — |
| Proceeds from issuance of common shares under 2022 Equity Incentive Plan | 132 | 369 |
| Other financing activities, net | — | — |
| Net cash provided by financing activities | 179,016 | 369 |
| Effects of exchange rates on cash, cash equivalents, and restricted cash | 16 | 23 |
| Net increase in cash, cash equivalents, and restricted cash | 44,326 | 147 |
| Cash, cash equivalents, and restricted cash at beginning of period | 232,779 | 102,542 |
| Cash, cash equivalents, and restricted cash at end of period | $277,105 | $102,689 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Biohaven's cash & equivalents?
- Biohaven (BHVN) reported cash & equivalents of $277.11M in Q1 2026.
- How has Biohaven's cash & equivalents changed year-over-year?
- Biohaven's cash & equivalents increased by 169.8% year-over-year, from $102.69M to $277.11M.
- What is the long-term trend for Biohaven's cash & equivalents?
- Over 5 years (2020 to 2025), Biohaven's cash & equivalents has grown at a 22.8% compound annual growth rate (CAGR), from $83.51M to $232.78M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Biohaven's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude